Redeye maintains its valuation of Orexo at SEK 80 per share after today's announcement of a successful pivotal study completion with OX124, Orexo's lead drug candidate. We have been expecting this outcome.
ANNONS
Redeye maintains its valuation of Orexo at SEK 80 per share after today's announcement of a successful pivotal study completion with OX124, Orexo's lead drug candidate. We have been expecting this outcome.